DAVID M. RODMAN, M.D.; MICHAEL HANLEY, M.D.; POLLY PARSONS, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Aminoglutethimide is an adrenal and peripheral blocker of steroid metabolism that has seen increasing use as a medical alternative to adrenalectomy. It has proved effective as therapy for patients with metastatic breast and prostate carcinomas, as well as those with functioning adrenal tumors (1). Adverse effects are usually transient and mild; however, serious adverse effects including bone marrow suppression, cholestasis, and systemic lupus erythematosus have been reported (2-4). We report a case of diffuse alveolar damage and hemorrhage associated with this drug.
A 47-year-old man with a known islet-cell tumor secreting corticotropin-releasing factor was started on aminoglutethimide,
RODMAN DM, HANLEY M, PARSONS P. Aminoglutethimide, Alveolar Damage, and Hemorrhage. Ann Intern Med. 1986;105:633. doi: https://doi.org/10.7326/0003-4819-105-4-633_1
Download citation file:
Published: Ann Intern Med. 1986;105(4):633.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use